Loading
Eribulin / Metastatic Triple Negative Breast Cancer / SDX-7320 · Phase 2 Trial
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registry record for an ongoing Phase 2 trial combining SDX-7320 with eribulin in triple-negative breast cancer, with insulin resistance as the primary endpoint. No results have been posted; the record describes only the planned design and rationale. The study is currently recruiting.
Phase 2, Interventional, Randomized, Sequential, Triple masking, Treatment purpose. Breast Cancer, Metastatic Triple-Negative Breast Cancer; age from 18 Years. Intervention: SDX-7320 plus Eribulin (safety run-in period); SDX-7320 plus Eribulin. Compared with: Eribulin Plus Placebo — Placebo Comparator. n = 55. 10 sites: United States.
This is a registry record for an ongoing Phase 2 trial combining SDX-7320 with eribulin in triple-negative breast cancer, with insulin resistance as the primary endpoint. No results have been posted; the record describes only the planned design and rationale. The study is currently recruiting.
This is a registry record; no efficacy or safety results have been reported.
The source did not state who this applies to in practice.
This is an active Phase 2 trial registration with no reported results; it describes a planned study of a combination approach in triple-negative breast cancer with a metabolic biomarker as primary outcome.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05570253). This is a study registration, not published results. Lead sponsor: Memorial Sloan Kettering Cancer Center. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 55 participants (ESTIMATED). Conditions: Breast Cancer, Metastatic Triple-Negative Breast Cancer. Interventions: DRUG: Eribulin; DRUG: SDX-7320; OTHER: Placebo. Primary outcome measures: change in insulin resistance scores (HOMA-IR) , 1 year. Brief summary: The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effective treatment for people with TNBC and metabolic dysfunction. The researchers will also look at whether the study treatment (SDX-7320 combined with eribulin) is safe and causes few or mild side effects in participants. The researchers will compare this treatment approach to eribulin alone.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.